BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/14/2019 9:57:12 AM | Browse: 1619 | Download: 2012
Publication Name World Journal of Gastroenterology
Manuscript ID 43226
Country United States
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies
Manuscript Source Invited Manuscript
All Author List Brian M Fung, Keith D Lindor and James H Tabibian
ORCID
Author(s) ORCID Number
Brian M Fung http://orcid.org/0000-0002-2558-5733
Keith D Lindor http://orcid.org/0000-0003-1046-5621
James H Tabibian http://orcid.org/0000-0001-9104-1702
Funding Agency and Grant Number
Corresponding Author James H Tabibian, MD, PhD, Health Sciences Clinical Associate Professor, David Geffen School of Medicine at UCLA, Director of Endoscopy, Olive View-UCLA Medical Center, 14445 Olive View Drive, 2B-182,, Sylmar, CA 91342, United States. jtabibian@dhs.lacounty.gov
Key Words Bile duct diseases; Cholangiocarcinoma; Gallbladder carcinoma; Hepatocellular carcinoma; Colorectal cancer; Chemoprotection; Inflammatory bowel disease
Core Tip Primary sclerosing cholangitis is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the bile ducts. It is associated with a significantly increased risk of malignancy over the general population, with nearly 50% of deaths in patients with primary sclerosing cholangitis caused by cancer, thus necessitating robust surveillance strategies. In this article, we provide a synopsis of the epidemiology, prevention, and surveillance of cancers in patients with primary sclerosing cholangitis.
Publish Date 2019-02-14 09:57
Citation Fung BM, Lindor KD, Tabibian JH. Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies. World J Gastroenterol 2019; 25(6): 659-671
URL https://www.wjgnet.com/1007-9327/full/v25/i6/659.htm
DOI https://dx.doi.org/10.3748/wjg.v25.i6.659
Full Article (PDF) WJG-25-659.pdf
Full Article (Word) WJG-25-659.docx